Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05415007 · ClinicalTrials.gov registry record · NA

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

A NA study of Cancer, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05415007: Recruiting NA study of Cancer, sponsored by Stanford University.

NCT05415007 is a NA study of Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05415007, a NA study of Cancer, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.

Conditions Studied

Interventions

  • BEHAVIORAL Treatment as usual (TAU)
  • BEHAVIORAL GOLD Program

Study Locations (1)

California

  • Stanford Cancer Institute - San Francisco

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-09-21
Est. Completion 2027-06-30
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT05415007

The ClinicalTrials.gov registry entry for NCT05415007 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Treatment as usual (TAU) is the first listed.

NCT05415007 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05415007 about?

NCT05415007 is a clinical study titled "GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer". The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.

What is the current status of trial NCT05415007?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2022-09-21. Estimated completion is 2027-06-30.

What conditions does trial NCT05415007 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT05415007?

The interventions under investigation include: Treatment as usual (TAU) (BEHAVIORAL), GOLD Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05415007?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05415007 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.